Yes, you can get terbinafine over the counter in the United States, and you have been able to since 1991, when the FDA approved the 1% topical cream (Lamisil AT) for nonprescription sale. In the UK, the same 1% cream has been available over the counter since 1993. What you cannot buy without a prescription in either country is oral terbinafine, the 250 mg tablet used for nail fungus and widespread skin infections. So the honest answer splits by formulation and by country: cream yes, tablets no, and the UK adds a pharmacist-gated pill for nail fungus that the US does not allow.
The Two Terbinafine Products People Confuse
Terbinafine comes in two forms that behave like different drugs even though the molecule is identical. The 1% cream reaches the skin surface and penetrates the stratum corneum, where it accumulates in the outer epidermal layers. The 250 mg tablet travels through the bloodstream to the nail matrix and the deeper dermis. The FDA approved the cream for over-the-counter use in 1991 and the tablet as prescription-only in 1996. That split is not arbitrary, and it drives every access question in this article.
The mechanism explains why the formulations are regulated differently. Terbinafine is an allylamine that inhibits squalene epoxidase, an enzyme early in the fungal ergosterol synthesis pathway. Blocking that step starves the fungus of ergosterol and causes toxic squalene to accumulate inside the cell. The drug is fungicidal against dermatophytes at concentrations the cream can achieve in skin, typically above 0.1 micrograms per gram of tissue. In plain terms: the cream kills the fungus where it lives on the skin, and the pill kills it where it lives in the nail.
Why the Cream Cleared the Counter and the Tablet Did Not
The regulatory logic comes down to systemic exposure. A fingertip of 1% cream delivers roughly 10 mg of terbinafine to the skin surface, and less than 5% of that crosses into the bloodstream. The 250 mg tablet puts the full dose into circulation, where it reaches the liver and interacts with other drugs. That difference in exposure is the entire reason one product sits on a shelf and the other sits behind a pharmacy counter.
Oral terbinafine carries a documented hepatotoxicity signal. The FDA label reports liver enzyme elevations in roughly 1 in 1,000 treated patients and rare cases of liver failure, which is why baseline liver function testing is advised before a course in patients with risk factors. The cream has no such requirement. The FDA approved the cream for athlete's foot, jock itch, and ringworm at 1% strength, and it remains one of the few genuinely fungicidal topical antifungals available without a prescription.
What the Cream Actually Treats
The over-the-counter cream handles superficial dermatophyte infections of the skin, not the nail. Its labeled indications are interdigital athlete's foot (tinea pedis), jock itch (tinea cruris), and body ringworm (tinea corporis). Cure rates from controlled trials hover around 70 to 80% for athlete's foot after one to two weeks of twice-daily application. That number matters because it is high enough to justify self-treatment for most healthy adults, but low enough that a third of users will need a second course or a prescription.
The cream does not work on nail fungus, and this is the most common misunderstanding that drives people to the pharmacy counter. A 1% cream cannot penetrate the nail plate to reach the matrix where the infection lives. Studies of topical terbinafine for onychomycosis show mycological cure rates under 10%, which is why the tablet exists. If the problem is in the nail, the cream is the wrong product regardless of what the box says.
The UK Exception: Pharmacist-Sold Tablets
The UK has a middle path the US does not offer. Since 2014, pharmacists in the UK can supply oral terbinafine 250 mg for confirmed dermatophyte nail infection under a pharmacy protocol, without a doctor's prescription. This is not a shelf product. You must speak to a pharmacist, confirm the diagnosis, and meet criteria such as a positive fungal sample or clear clinical signs. The pharmacist then supplies a course of up to 12 weeks for toenails or 6 weeks for fingernails.
That 12-week figure reflects the slow growth of the toenail, which advances roughly 1 mm per month. A full big toenail takes 12 to 18 months to regrow, so even a successful 12-week course leaves visibly damaged nail behind until new growth replaces it. The drug works during the course; the cosmetic result lags months behind. In the US, this pharmacist-supply route does not exist, and oral terbinafine remains prescription-only in every state.
Topical Versus Oral: A Quantified Comparison
The table below reconciles the cure rates, durations, and access rules that separate the two formulations. These numbers come from labeled indications and controlled trial data, and they should be read as typical ranges rather than guarantees.
| Feature | 1% topical cream | 250 mg oral tablet |
|---|---|---|
| US access | Over the counter since 1991 | Prescription only |
| UK access | Over the counter since 1993 | Pharmacist supply or prescription |
| Best indication | Skin dermatophyte infections | Nail and extensive skin infections |
| Typical cure rate | 70 to 80% (athlete's foot) | 70 to 80% (nail, after full course) |
| Treatment duration | 1 to 2 weeks | 6 to 12 weeks |
| Systemic absorption | Under 5% of applied dose | Full dose into circulation |
| Liver monitoring | Not required | Advised in at-risk patients |
| Cost | USD 10 to 20 per tube | USD 30 to 60 per course |
The cure-rate symmetry is the counterintuitive part: both formulations land in the same 70 to 80% range, but for different diseases. The cream wins on access and safety; the tablet wins on reach into the nail. Neither is universally better, which is why the choice depends on where the fungus lives.
Red Flags That Push You to a Prescription
Self-treatment with the cream is reasonable for a healthy adult with a clear skin infection. It is not reasonable in several situations, and these are the cases where the over-the-counter route fails or is unsafe.
- The infection is in the nail, not the skin, and has been present for more than a few weeks.
- The infection covers a large area, involves the scalp, or keeps returning after two full courses of cream.
- You have diabetes, poor circulation in the feet, or a weakened immune system.
- The skin is broken, weeping, or showing signs of bacterial infection such as spreading redness or fever.
- You take medications that interact with oral terbinafine, including certain antidepressants and blood thinners.
- You have known liver disease or a history of abnormal liver tests.
Each of these pushes the decision from self-care to clinical assessment. The cream is cheap and safe, but it cannot compensate for a diagnosis it was never designed to treat.
How Long Each Route Takes to Work
The time course differs sharply between the two formulations, and this timeline explains why people abandon treatment early and assume it failed.
| Timepoint | Topical cream | Oral tablet |
|---|---|---|
| Day 1 | First application, surface drug deposition | First dose, drug enters bloodstream |
| Week 1 | Itch and scaling begin to reduce | Early skin improvement possible |
| Week 2 | Most athlete's foot cases clinically clear | Skin symptoms often improved |
| Week 4 | Course typically complete | Nail drug levels stabilize |
| Week 6 | Relapse check if symptoms return | Fingernail course may end |
| Week 12 | New skin fully established | Toenail course may end |
| Month 6 to 12 | Not applicable | New nail growth visibly replaces damaged plate |
The plain-language takeaway: the cream works on a two-week clock, and the tablet works on a three-month clock, but the visible nail result lags six to twelve months behind the end of treatment. Expecting a clear toenail at week 12 is the single most common reason people think oral terbinafine failed when it actually worked.
Misconceptions and Edge Cases
The most persistent misconception is that the cream and the tablet are interchangeable at different doses. They are not. Doubling the cream does not reach the nail, and halving the tablet does not treat skin faster. The formulations are matched to tissue, not to severity.
A second misconception concerns resistance. Terbinafine resistance in dermatophytes is rare but rising, and it is documented most often in Trichophyton indotineae, particularly in South Asia. In the US, resistance remains uncommon as of 2026, but the trend means a treatment that fails twice deserves a culture rather than a third course. This is a hypothesis-level concern for most patients, not an established reason to avoid the drug.
A genuine edge case involves the drug interaction profile of the tablet. Oral terbinafine inhibits CYP2D6, an enzyme that metabolizes many antidepressants, beta-blockers, and opioids. That interaction can raise blood levels of those drugs within days. The cream does not meaningfully inhibit CYP2D6 because so little reaches the liver. This is another reason the tablet stays prescription-only: the pharmacist and prescriber need to check the medication list before the first dose.
What to Actually Do
If you have a skin infection and no red flags, start with the over-the-counter 1% cream and apply it twice daily for one to two weeks, continuing for a few days after the skin looks clear. Keep the area dry and change socks or underwear daily. If the infection has not improved after two full courses, stop self-treating and see a clinician.
If the problem is in the nail, do not buy the cream. In the US, book a clinician visit for a prescription and a confirmatory fungal test, which typically costs USD 50 to 150 and takes one to three weeks to return. In the UK, ask a pharmacist about the supply protocol and bring any prior test results. Ask about baseline liver tests if you have risk factors or take interacting medications.
Limits of the Over-the-Counter Route
The over-the-counter route has real boundaries that no amount of label-reading can overcome. It cannot diagnose, it cannot reach the nail, and it cannot check your medication list. The 70 to 80% cure rate for athlete's foot is genuine, but the remaining 20 to 30% of cases need either a different topical agent or a prescription. Recognizing that boundary early saves weeks of failed self-treatment and, in the case of nail infection, months of watching a problem that only a tablet can fix.